Esco Announces Nearly $10 Million Strategic Investment in Dewin Medical to Advance Domestic Assisted Reproductive Technology Solutions
On November 6, at the 4th China International Import Expo, Esco (Jiangsu) Biotechnology Co., Ltd. (hereinafter referred to as “Esco”) announced the completion of a strategic investment of nearly USD 10 million in Dongyun Medical Technology (Shanghai) Co., Ltd. (hereinafter referred to as “Dongyun Medical”), and held an on-site signing ceremony. Going forward, the two parties will deeply integrate their resources, comprehensively deploy in the field of assisted reproductive medical devices, provide full-process product solutions for assisted reproduction, and jointly explore new prospects in the assisted reproduction market.
By the end of 2020, the total number of assisted reproductive technology (ART) service cycles in China reached 1.303 million, with a compound annual growth rate (CAGR) of 15% from 2016 to 2020. Currently, there are 517 medical institutions in China approved to provide ART services. Based on the total number of ART service cycles in 2020, the average number of service cycles per institution exceeded 2,600. At present, 9.6 million couples suffering from infertility require ART services, bringing the total market demand for assisted reproductive technology to RMB 434.1 billion.
Upstream medical devices in the assisted reproductive technology (ART) industry chain primarily include ART consumables (such as embryo freezing/thawing media, embryo culture media, etc.) and specialized instruments. In terms of overall market share, 95% of high-value ART consumable devices rely on imports, with embryo culture media being monopolized by foreign brands; no domestically approved products have yet been launched on the market.
Yin Hang, Co-founder and General Manager of Dongyun Medical, stated, “Dongyun Medical is a supplier in China that independently develops and innovates, providing a full suite of domestically produced embryo culture media as well as reagents for oocyte and sperm processing. Our products integrate years of research findings and clinical experience from scientists, physicians, and embryologists, ideally replicating the natural growth environment of embryos.” Dongyun Medical has established a comprehensive production and quality control management system for embryo culture media and micromanipulation products. The company has built an integrated facility for production, testing, and R&D, which includes high-standard clean production workshops, automated production lines, quality control workshops, cold-chain storage, and R&D laboratories.
As a division of Esco, Esco Medical is a provider of assisted reproductive technology (ART) and solutions, dedicated to improving patient pregnancy outcomes and enhancing user satisfaction by standardizing and automating ART service processes. In addition to leveraging its own business strengths to explore new solutions, Esco actively collaborates with local innovative enterprises to lead trends in healthcare.
“In the future, Esco will join hands with Dongyun Medical to comprehensively promote the full range of upstream products for assisted reproductive technology (ART). The two parties will deeply integrate advanced technological and market resources both domestically and internationally, accelerating the localization of ART-related products, as well as reagents and consumables for ART laboratories. We believe this collaboration will deliver more comprehensive solutions to the ART market, meeting the growing demand in China and globally, and contributing to the cause of eugenics and healthy childbirth,” said Lin Xiangqian, Chairman and CEO of Esco.
Dongyun Medical, founded in 2017 and headquartered in the Lingang Pujiang International Science and Technology City in Shanghai, China, specializes in the field of assisted reproduction. Co-founder Professor Yin Hang previously served at Weill Cornell Medicine in the United States. Dongyun Medical’s product portfolio is driving the substitution of imported products, with a deep-rooted corporate culture that emphasizes attention to detail and a commitment to innovation. The company aims to provide high-quality products for couples facing infertility, achieving optimal clinical outcomes and benefiting more families.
Esco, established in 1978, specializes in providing enabling technologies, products, and services to the life sciences and healthcare industries. It supports academic and scientific research, clinical practice, as well as the research, development, and manufacturing of biopharmaceuticals. With eight production and R&D centers located in the United States, Europe, the United Kingdom, China, Singapore, and Indonesia, Esco now operates more than 30 subsidiaries and employs over 1,700 people, delivering its products and services to more than 100 countries worldwide.